The stakes are high as a drug moves through clinical development, which accounts for more than 70% of the R&D cost needed to bring it to market. As the biopharmaceutical industry increasingly turns its focus to discovering and delivering targeted, personalized medicines, many of the old, well-tested strategies for developing cancer drugs are no longer relevant. Gaining access to patients in a clinical setting requires a new strategy, with biomarkers an integral part of the story. The need for novel cancer treatments, especially those requiring patients in typically smaller populations, shows no sign of decreasing.
M2Gen®, a subsidiary of Moffitt Cancer Center, has built the Total Cancer Care TM data warehouse of over 100,000 patients and more than 35,000 tumor specimens, making it the most robust cancer-focused resource of its kind anywhere in the world. A new partnership with Covance can help you translate clinical trial matching expertise and clinical trial design to increase your clinical trial success.
This webinar and panel discussion focuses on new ways to design biomarker driven trials and access the right patients, will demonstrate the power of the Total Cancer Care TM data warehouse, and will feature participation from Millennium Pharmaceuticals.*************
Access to this webinar is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.
If you require help with your registration or have any questions you may contact Xtalks at: email: email@example.com; phone: 416-977-6555, x 371.
By completing this registration form, you agree that the information you have provided is true and accurate.
(note: fields with marked "*" are required)